NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Ventus Therapeutics

Ventus Therapeutics

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://www.ventustx.com/

Last Round

Grant

Apr 20, 2023

Total Funding Raised

$300.15M

Company Overview

Ventus Therapeutics is a biopharmaceutical company that develops small-molecule medicines targeting proteins in the inflammasome and nucleic acid-sensing signaling pathways to address acute and chronic inflammatory and immune-related diseases.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

computational drug discoverystructural biologyNLRP3 inhibitorsmall-molecule therapeuticsdrug discovery platformcGAS inhibitorneuroinflammationundruggable targetsAI drug discoveryin silico drug designbiotech R&Dbrain-penetrant drugspharma licensingAI-first biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Ventus Therapeutics Comparables

Compare Ventus Therapeutics with similar companies based on industry and business-model similarity.

Ventus Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
IFM Therapeutics
85%
Halia Therapeutics
82%
Beren Therapeutics
82%

Ventus Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantApr 20, 2023
Series CFeb 9, 2022
Series BApr 8, 2021
Series AMay 6, 2020

Key People

Founding team and executive leadership

Christine Ha

Chief Financial Officer

Executive Team

Daniel Koerwer

Chief Operating Officer

Executive Team

Ventus Therapeutics Investors

Notable investors and investment history

Ventus Therapeutics investors
InvestorRounds
Andreessen HorowitzSeries C
SoftBank Investment AdvisersSeries C
RA Capital ManagementSeries C, Series B
GVSeries C, Series A, Series B
Cormorant Asset ManagementSeries C, Series B
Fonds de solidarité FTQSeries C, Series B
SoftBank GroupSeries C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 21, 2025

    Partnered with Genentech to develop small-molecule drugs.

  • Sep 4, 2025

    Will present at the Morgan Stanley Global Healthcare Conference.

Ventus Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Ventus Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Ventus Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range55
Year Founded2019
Last FundingApr 20, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.